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Abstract 
Epstein-Barr virus (EBV) latency has been associated with a variety of hu-
man cancers. Latent membrane protein 1 (LMP-1) is one of the key viral pro-
teins required for transformation of primary B cells in vitro and establishment 
of EBV latency. We have previously shown that LMP-1 induces the expres-
sion of several interferon (IFN)-stimulated genes and has antiviral effect 
(Zhang, J., Das, S. C., Kotalik, C., Pattnaik, A. K., and Zhang, L. (2004) J. 
Biol. Chem. 279, 46335–46342). In this report, a novel mechanism related to 
the antiviral effect of LMP-1 is identified. We show that EBV type III latency 
cells, in which LMP-1 is expressed, are primed to produce robust levels of en-
dogenous IFNs upon infection of Sendai virus. The priming action is due to 
the expression of LMP-1 but not EBV nuclear antigen 2 (EBNA-2). The sig-
naling events from the C-terminal activator regions of LMP-1 are essential to 
prime cells for high IFN production. LMP-1-mediated activation of NF-κB 
is apparently necessary and sufficient for LMP-1-mediated priming effect in 
DG75 cells, a human B cell line. IFN regulatory factor 7 (IRF-7) that can be 
activated by LMP-1 is also implicated in the priming action. Taken together, 
these data strongly suggest that LMP-1 may prime EBV latency cells for IFN 
production and that the antiviral property of LMP-1 may be an intrinsic part 
of EBV latency program, which may assist the establishment and/or mainte-
nance of viral latency.
Abbreviations: EBV, Epstein-Barr virus; LMP-1, latent membrane protein 
1; HA, hemagglutinin; IFN, interferon; IRF-7, IFN regulatory factor 7; NF-
κB, nuclear factor κB; IκB, inhibitor κB; ISG, IFN-stimulated gene; FBS, fe-
tal bovine serum; RPA, RNase protection assays; BL, Burkitt’s lymphoma; 
EBNA, EBV nuclear antigen; CTAR, C-terminal activator region; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; ELISA, enzyme-linked immu-
nosorbent assay.
Introduction 
 Epstein-Barr virus (EBV) is a human γherpesvirus and is an impor-
tant cause of lymphomas in patients with advanced human immu-
nodeficiency virus infection or AIDS and in severely immunocom-
promised people, especially organ transplant recipients. Also, EBV 
infection is associated with the development of nasopharyngeal car-
cinoma and Burkitt’s lymphoma (BL) (1,2). 
The biologic hallmark of EBV-cell interaction is latency. Three 
types of latency have been described, each having its own distinct 
pattern of gene expression. Type I latency is exemplified by BL tu-
mors in vivo. EBV nuclear antigen 1 (EBNA-1) protein is expressed 
in this form of latency. Type II latency is exemplified by nasopha-
ryngeal carcinoma and Hodgkin disease. EBNA-1, latent membrane 
protein 1 (LMP-1), and LMP2A and LMP2B proteins are expressed 
in type II latency. Type III latency is represented by lymphoblastoid 
cell lines. Nine viral proteins are expressed, including six nuclear 
proteins (EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, and 
EBNA-LP) and three integral membrane proteins (LMP-1, LMP-2A, 
and LMP-2B) (reviewed in references 1 and 2). 
EBV LMP-1 is the principal oncoprotein required for EBV trans-
formation of human B cells and establishment of latency in vitro. 
LMP-1 is an integral membrane protein with six transmembrane-
spanning domains with a long C-terminal domain, which is located in 
the cytoplasm (2, 3). Two C-terminal activator regions (CTARs) have 
been identified to initiate signal transduction. LMP-1 acts as a consti-
tutively active receptor-like molecule that does not need the binding 
of a ligand (4). LMP-1 appears to be a central effector of altered cell 
growth, survival, adhesive, invasive, and antiviral potential (5–9). 
Type I interferons (IFNs) are cytokines with many functions in-
cluding antiviral and anti-proliferation (10, 11). IFNs are produced 
upon the infection of cells by viruses. There are a large number of 
type I IFN genes in the human: 13 IFN-α genes, 1 IFN-β gene, and 1 
IFN-ω gene (12). It is not known now why there are so many type I 
IFN genes. However, a unique role for IFN-β for a fully effective an-
tiviral response, which cannot be compensated by IFN-α, has been 
documented (13). 
The amount of IFNs produced by viruses or double-stranded RNA 
can be increased robustly by treating cells with IFN before infec-
tion, a phenomenon known as IFN priming (14–16). The stimulation 
of IFN production observed upon priming results from an increase 
in the rate of IFN gene transcription and requires an IFN-inducible 
factor(s) (17, 18). 
The mechanism of the transcriptional activation of IFNs has been 
under intensive investigation. One of the major players in the IFN 
production is IFN regulatory factor 7 (IRF-7). IRF-7 was cloned in 
the context of EBV latency and has an intimate relation with EBV 
(19–25). IRF-7 is inducible by type I IFNs and can be further acti-
vated by phosphorylation and nuclear translocation upon viral infec-
tion, and activated IRF-7 is partially responsible for the robust tran-
scriptional activation of IFNs (23, 26–29). 
Previously, we have shown that LMP-1 induces several antiviral 
IFN-stimulated genes (ISGs) without triggering IFN production and 
that LMP-1 possesses antiviral activity (30). In this report, we ex-
tend our earlier discovery and show that EBV latency cells have en-
hanced ability to produce IFN upon viral superinfection. We further 
show that LMP-1 primes EBV latency cells for IFN production, sim-
ilar to IFN primed cells. To our knowledge, this is the first report that 
a viral latent gene primes cells for IFN production. 
Experimental Procedures 
 Plasmids, Antibodies, and Viruses—Expression plasmids of 
LMP-1 and its signaling-defective mutant, LMP-DM, as well as IRF-
7 and its DNA-binding mutant, IRF7-K92E, were described previ-
ously (24, 31). Expression plasmid of EBNA-2 (pAG155) was a gift 
from Dr. Paul Ling. NF-κB -related plasmids p65 and p50, IκB ex-
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pression plasmids, plus NF-κB reporter construct were gifts from Dr. 
Albert Baldwin. EBNA-2 antibody (PE2) and LMP-1 antibody (CS1–
4) were purchased from Dako. STAT-1 antibody was purchased from 
Santa Cruz Biotechnology. Tubulin antibody was purchased from 
Sigma. Anti-Sendai virus antibody was purchased from U. S. Bio-
logical. Recombinant human IFN-α was purchased from Schering-
Plough. Sendai virus stock was purchased from Spafas, Inc. For vi-
rus infection, 200 HA units/ml Sendai virus were added to the target 
cells for 6 h, and cells were then collected for RNA isolation. How-
ever, 7-h infection was used for examining the endogenous IFN pro-
duction in the media. 
Cell Culture, Transient Transfection, and Isolation of Transfected 
Cells—DG75 is an EBV-negative Burkitt’s lymphoma cell line (32). 
BL41 is an EBV-negative BL line, and BL41-EBV was generated by 
in vitro infection of BL41 with EBV B95-8 strain (33). Sav I and Sav 
III are genetically identical cell lines that differ only in their latency 
types (34). Akata (type I) and IB4 (Type III) are EBV-positive cell 
lines. These cells were maintained in RPMI 1640 plus 10% fetal bo-
vine serum (FBS). 293 cells are human fibroblasts and are maintained 
in Dulbecco’s modified Eagle’s medium plus 10% FBS. Electropora-
tion (320 V; 925 microfarads) was used for transfection of the B cells 
as described previously (20, 21, 24). A total 10 µg of DNA was used 
for transfection of DG75 cells. 1 µg of LMP-1-expression plasmids 
were always used in transfection because similar LMP-1 expression 
levels in transfected and EBV type III latency cells could be achieved 
under such conditions. Enrichment for CD-4-positive cells was per-
formed with the use of anti-CD-4-antibody conjugated to magnetic 
beads according to the manufacturer’s recommendation (Dynal, Inc.). 
DG75 cells were transfected with CD-4 expression and other plas-
mids. One day after the transfection, the cells were used for isolation 
of CD-4-positive cells with the use of Dynabeads CD4 (Dynal Inc.) 
The transfected cells were incubated with Dynabeads-CD4 at 72 µl of 
beads/107 cells for 20–30 min at 4 °C with gentle rotation. CD4-pos-
itive cells were isolated by placing the test tubes in a magnetic sep-
aration device (Dynal magnet). The supernatant was discarded while 
the CD4-positive cells were attached to the wall of the test tube. The 
CD4-positive cells were washed 4–5 times in phosphate-buffered sa-
line plus 2% FBS and resuspended in 100 µl of RPMI 1640 plus 1% 
FBS. Cells were detached from the Dynabeads CD4 by incubating 
for 45–60 min at room temperature with 10 µl of DETACHaBEAD 
(Dynal). The detached beads were removed by using the magnet sep-
aration device. The released cells were washed 2–3 times with 500 µl 
of RPMI 1640 plus 10% FBS and resuspended in RPMI 1640 plus 
10% FBS at 5 × 105 cells/ml. The isolated cells were used to extract 
total RNAs or prepare cell lysates immediately or recovered over-
night before infection by viruses. 
Western Blot Analysis with Enhanced Chemiluminescence 
(ECL)—Separation of proteins on SDS-PAGE was carried out fol-
lowing standard protocol. After the proteins were transferred to a ni-
trocellulose or Immobilon membrane, the membrane was blocked 
with 5% nonfat dry milk in TBST (50 mM Tris-HCl, pH 7.5, 200 
mM NaCl, 0.05% Tween 20) at room temperature for 10 min. It was 
then washed briefly with TBST and incubated with the primary anti-
body in 5% milk in TBST for 1 h at room temperature or overnight at 
4 °C. After washing with TBST three times (10 min each), the mem-
brane was incubated with the secondary antibody at room tempera-
ture for 1 h. It was then washed three times with TBST, treated with 
ECL detection reagents (Amersham Biosciences), and exposed to 
Kodak XAR-5 film. 
RNA Extraction, RNase Protection Assays (RPA), and Reporter 
Assays—Total RNA was isolated from cells using the RNeasy total 
RNA isolation kit (Qiagen, Valencia, CA) or TRIzol extraction. RPA 
was performed with 10 µg of total RNA using the RNase protection 
assay kit II (Ambion, Houston, TX) at 55 °C. Sometimes, gradient 
temperatures were performed for RPA when difficulties in RPA were 
encountered (35). The GAPDH probe was from U. S. Biochemicals. 
The probe for IFN-β was a gift from Dr. Ganes Sen. The luciferase 
reporter assays were performed using the assay kit from Promega ac-
cording to manufacturer’s recommendation. 
Removal of Sendai Virus from Culture Medium—The removal 
of Sendai virus was achieved by the use of 15-nm Planova virus re-
moval filters (gifts from Asahi Kasei, Pharma Corp.). Seven hours af-
ter Sendai virus infection, cell culture media were collected and passed 
through the Planova filters following the manufacturer’s protocol. To 
test whether the filtered media contain Sendai viruses, the filtered con-
ditional media were used to treat fresh BL41 cells, and the cell lysates 
were made 24 h later. Western blot with anti-Sendai antibody was used 
to detect any Sendai proteins in cell lysates. Sendai virus-treated (20 
HA units/ml) cell lysates were used as positive controls. 
IFN-α Measurement and Functional Assay—The concentration 
of IFN-α was determined by a commercially available human inter-
feron α(Hu-IFN-α) ELISA kit (PBL Biomedical Laboratories; cat-
alog number 41100) according to the manufacturer’s recommenda-
tions. The kit is able to detect human IFN-αA, IFN-α2, IFN-αA/D, 
IFN-αD, IFN-αK, and IFN-α4b. However, it cannot detect IFN-β, 
IFN-ω, and other IFN-α subtypes. Samples were examined in tripli-
cates. To test the functions of IFNs in cell culture media, the condi-
tional media were first passed through a 15-nm filter to remove Sen-
dai viruses. These media were then used to treat fresh BL41 cells at 
desired dilutions for 24 h, and cell lysates were used for the detec-
tion of STAT-1 expression. The human IFN-α neutralization antibody 
(RDI-PB31130) was purchased from Fitzgerald Industries Intl. The 
antibody is able to react with several kinds of IFN-α subtypes but 
not IFN-β and IFN-ω. 100,000 neutralization units/ml were added to 
BL41 cells along with suitable concentration of conditional media 
and incubated for 24 h. The expression of STAT-1 in BL41 cells was 
then measured by Western blot analyses. 
Results 
EBV Type III Latency Cells Have Higher Capacity to Produce 
IFN-β—It is well known that EBV type III latency expresses high 
levels of IRF-7 and other ISGs, similar to IFN-treated cells. Because 
IFN can prime the cell for robust IFN production, whether these EBV 
latency cells are primed for higher IFN production upon viral super-
infection was examined. BL41 is an EBV-negative Burkitt’s lym-
phoma line, and BL41-EBV is its EBV-infected derivative with type 
III latency. Sav I (type I latency) and Sav III (type III latency) are ge-
netically identical sister cell lines that differ only in their types of la-
tency. These two pairs of cell lines were used to address the presence 
of EBV type III latency on the production of IFN. Sendai virus was 
used to infect these cells, and total RNA was isolated 6 h after infec-
tion. RPA experiments were used for the detection of IFN-β  RNA 
production. As shown in Figure 1A, whereas BL41 and Sav I cells 
had little or no detectable IFN-β production, high IFN-β RNAs were 
observed in BL41-EBV and Sav III cells, both of which are type III 
latency cells with LMP-1 expression (Figure 1B). We also tested 
IFN-β production in Akata (type I latency) and IB4 (type III latency) 
cells upon on Sendai infection. Although IB4 could produce high lev-
els of IFN-β, Akata cells failed to produce a significant amount (data 
not shown). These data suggest that the induction of IFN-β upon vi-
ral infection is enhanced in EBV type III latency cells. 
EBV Type III Latency Cells Produce Functional Type I IFNs upon 
Superinfection—Type I IFNs are a family of IFN-α, one IFN-β, and 
one IFN-ω. However, using IFN-β as an indicator for type I IFN 
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production is well established and appreciated in the field (26, 28, 29, 
31). Thus, the results in Figure 1 suggest that type I IFNs were robustly 
induced in EBV latency cells. Because IFN-β RNA is synthesized in 
EBV-infected cells and because EBV and other herpesviruses encode 
genes to shut off host gene expression (36–40), it is thus necessary to 
examine whether IFN proteins are synthesized and secreted properly. 
ELISA was used for the detection of IFN-α proteins in the culture me-
dia. As shown in Figure 2A, the Sendai virus-infected BL41-EBV cells 
produced huge amount of IFN-α. However, uninfected cells and in-
fected BL41 cells produced undetectable levels of IFN-α, which was 
in agreement with the data in Figure 1. These results indicate that IFNs 
are properly synthesized and secreted from EBV latency cells. Whether 
these secreted IFNs were functional was tested. The media from Sendai 
virus-infected or -uninfected cells were collected and passed through 
15-nm filters. It is well established that a 15-nm filter is able to elimi-
nate Sendai viruses (41). We confirmed that the filtered media did not 
contain detectable Sendai viruses as determined by viral protein ex-
pression (data not shown). These conditional media were then used to 
treat fresh BL41 cells with various dilutions and to determine the ex-
pression of STAT-1 24 h later. The reasons to use STAT-1 as an indi-
cator of IFN functions are because STAT-1 is highly inducible by IFN 
and Sendai virus blocks IFN signaling (42–45). Therefore, a success-
ful induction of STAT-1 may suggest the presence of functional IFNs 
and absence of Sendai viruses. As shown in Figure 2B, the conditional 
medium from BL41-EBV-superinfected cells was  ~10-fold more po-
tent than that from BL41-infected cells for induction of STAT-1. The 
apparent discrepancy between Figure 2A (column 2) and 2B (lanes 3–
6) might be due to the fact that the ELISA kit only detects a subset of 
IFN-α (see “Experimental Procedures” for details) and/or that viral su-
perinfection has produced other secretable factors that are capable of 
inducing STAT-1. Of note is the fact that LMP-1 has been shown to 
produce a soluble factor(s) that induces STAT-1 (46). Whether IFNs 
in the conditional media were responsible for the induction of STAT-1 
was tested with the use of IFN-α neutralization antibody. As shown in 
Figure 2C, the human IFN-α neutralization antibody partially inhibited 
the induction of STAT-1. Therefore, type III latency cells had produced 
functional IFNs, and IFN-β RNA was a good indicator for the robust 
type I IFN production in this system. The data in Figures 1 and 2 col-
lectively suggest that EBV type III latency cells are primed for type I 
IFN production. 
LMP-1 Primes Cells for the Expression of IFNs—EBV latency 
cells apparently cannot produce IFNs, based on our previous results 
and those of others (30, 47–49). As a matter of fact, Figure 2 clearly 
showed that EBV latency cells (BL41-EBV) did not produce signif-
icant amounts of IFNs without viral infection (Figure 2A, column 3, 
and B, lane 7). Thus, the priming effect of EBV latency cells is likely 
to be the function of an EBV latent protein(s) rather than the produc-
tion of IFN by latency cells per se. 
Figure 1.  EBV latency cells are primed to produce robust IFN-β upon 
superinfection. A, EBV type III latency cells produce higher levels of IFN-
β upon superinfection of Sendai virus. BL41, BL41-EBV, Sav I, and Sav III 
cells were infected by Sendai virus (200 HA units/ml) for 6 h. Total RNAs 
were isolated and used for RPA with IFN-β and GAPDH probes. Yeast 
RNA was used as negative control. Specific protections of IFN-β and 
GAPDH RNAs are indicated. B, expression of LMP-1 in EBV latency cells. 
Lysates from BL41, BL41-EBV, Sav I, and Sav III were used for Western 
blot analysis with LMP-1 and tubulin antibodies. The identity of proteins is 
as shown. +/–, with or without virus infection.
Figure 2.  IFNs produced by superinfection of EBV latency cells are functional. A, IFNs are secreted into the culture media. BL41 and BL41-EBV 
cells were infected by Sendai virus (200 HA units/ml) for 7 h. The cell culture media were collected, and the concentrations of IFN-α were measured with 
the use of ELISA. Standard deviations are shown. +/–, with or without Sendai virus infection. B, the conditional media from EBV type III latency cells in-
fected by Sendai virus induces higher levels of STAT-1. BL41 and BL41-EBV were infected with (+) or without (–) Sendai (200 HA units/ml) for 7 h. Cell 
culture media were collected, and Sendai viruses were removed by passing through 15-nm Planova virus removal filters. The filtered conditional media 
were used to treat fresh BL41 cells at indicated dilution factors. After 24 h, cell lysates were prepared and used for Western blot analyses with STAT-1 and 
tubulin antibodies. The identity of proteins is as shown. C, IFN-α is involved in the induction of STAT-1. BL41 cells were treated with the conditional media 
(1:100, from BL41-EBV cells superinfected with Sendai), the neutralization antibody (Ab) of IFN-α, and the same amounts of normal rabbit serum (NRS) in 
various combinations as shown on the top. The expression of STAT-1 was examined 24 h later. The identity of proteins is as shown.
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There are several viral genes expressed in EBV type III latency. 
However, because LMP-1 induces IRF-7 and other ISGs and has an-
tiviral effect without inducing IFNs (20, 24, 30, 47) and because IRF-
7 is a master gene for IFN production (50), LMP-1 apparently is a 
good candidate for the priming action. In addition, EBNA-2, the pri-
mary inducer of LMP-1 (51–54), might play a role for the priming of 
the latency cells. DG75 cells, which are EBV-negative Burkitt’s lym-
phoma cells, were used for the experiments because of transfection 
efficiency. Vector, LMP-1, or EBNA-2 and a CD4 expression plas-
mid were transfected into cells. Transfected cells were enriched and 
split into two wells, one of which was infected by viruses. As shown 
in Figure 3A, LMP-1 caused a marked increase in IFN-β RNA lev-
els in DG75 cells; however, EBNA-2 did not enhance the expression. 
The expression of EBNA-2 is confirmed by Western blot (data not 
shown). Therefore, LMP-1, but not EBNA-2, is probably responsible 
for the priming effect of type III latency cells. In addition, if EBNA-2 
is involved in the priming, it is likely to do so indirectly via induction 
of LMP-1 in EBV-infected cells. 
It is of note that the LMP-1-mediated priming effect is similar to 
IFN priming (Figure 3B). However, due to the fact that LMP-1 did 
not induce IFN in DG75 cells in our system (30), the priming effect 
must be due to gene(s) regulated by LMP-1. 
Signaling Derived from LMP-1 Is Required for the Priming Ef-
fect—LMP-1 is an integral membrane protein with two regions in 
the C terminus (CTARs) that have been shown to initiate signaling 
processes including the activation of NF-κB and IRF-7. LMP-DM is 
a mutant of LMP-1 in both CTARs that fails to activate NF-κB and 
IRF-7 (24). LMP-1 or LMP-DM and a CD4 expression plasmid were 
transfected into DG75 cells, and the priming effect of LMP-1 was 
examined. As shown in Figure 4, whereas LMP-1 caused a marked 
increase in IFN-β RNA, LMP-DM seemed to have no effect. The 
expression of LMP-1 proteins was confirmed (Figure 4B). Thus, sig-
naling from LMP-1 CTARs is required for the priming action. 
NF-κB Is Necessary and Sufficient for LMP-1-mediated Priming 
in DG75 Cells—Next, the roles of intracellular molecules involved in 
LMP-1-mediated priming action were examined. Because both LMP-
1 CTARs can activate NF-κB and because NF-κB plays a pivotal role 
in the viral latency, whether NF-κB is involved in LMP-1-mediated 
priming was examined. As shown in Figure 5A, LMP-1 alone primed 
cells for high IFN production. However, in the presence of IκB, the 
priming effect of LMP-1 was completely abolished. IκB was able to 
block LMP-1-mediated activation of  NF-κB (data not shown). 
Because overexpression of NF-κB is capable of induction of IRF-
7 in DG75 cells, we asked whether NF-κB activation alone might 
be contributing to the priming process of LMP-1. As shown in Fig-
ure 5A, overexpression of NF-κB (p65 + p50) was sufficient to prime 
cells for IFN production in DG75 cells. The activation of NF-κB 
by p65 and p50 was confirmed by NF-κB reporter assays (data not 
shown). Thus, the data in Figure 5 suggest that NF-κB is involved in 
LMP-1-mediated priming action. 
IRF-7 May Be a Factor Involved in the Induction—Because 
LMP-DM failed to induce IRF-7 and NF-κB is required for induction 
of IRF-7 (24), the data in Figures 4 and 5 also suggest the potential 
involvement of IRF-7 in the priming process of LMP-1. In addition, 
the essential role of IRF-7 in type I IFN production has been well 
established (26–28, 50). IRF-7 and its DNA-binding mutant (IRF-
7K92E) were used for transfection, and their roles in LMP-1-medi-
ated priming action were examined. As shown in Figure 6, whereas 
wtIRF-7 was capable of priming the transfected cells, IRF-7 DNA-
binding mutant (IRF-7K92E) failed to prime the cells. These data 
suggest that induction of IRF-7 by LMP-1 may be an important step 
in priming cells for IFN production. 
Figure 3.  LMP-1 primes cells for IFN production. A, LMP-1-express-
ing cells have robust IFN production upon viral infection. DG75 cells were 
transfected with pcDNA3, LMP-1, or EBNA-2 expression plasmids. The 
transfected cells were isolated and equally split into two wells; one well of 
the cells was infected with Sendai virus for 6 h. Total RNA were isolated 
and used for RPA with IFN-β plus GAPDH probes. Yeast RNA was used 
as negative control. Specific protections of IFN-β and GAPDH RNAs are 
indicated. +/–, with or without virus infection. B, IFN primes DG75 cells. 
DG75 were treated with IFN-α (200 IU/ml) overnight, and the cells were in-
fected by Sendai virus for 6 h. Total RNA were isolated and used for RPA. 
+/–, with or without virus infection.
Figure 4.  Signaling events from LMP-1 are required for robust IFN 
production. A, LMP-1 mutant fails to prime IFN production upon viral in-
fection. DG75 cells were transfected with pcDNA3, LMP-1, or LMP-DM 
expression plasmids. The transfected cells were isolated, and half of the 
cells were infected with Sendai virus for 6 h. Total RNA were isolated and 
used for RPA with IFN-β plus GAPDH probes. Yeast RNA was used as 
negative control. Specific protections of IFN-β and GAPDH RNAs are indi-
cated. +/–, with or without virus infection. B, expression of target proteins 
in transfected cells. Lysates from transfected and enriched DG75 cells 
were used for Western blot analysis with LMP-1 and tubulin antibodies. 
The identity of proteins is as shown.
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Discussion 
 
It is well established that IFN primes cells for robust IFN produc-
tion upon viral infection. In this report, we show that EBV type III la-
tency cells are also primed for robust IFN production (Figures 1 and 
2). Because current evidence suggests that EBV latency cells cannot 
produce type I IFNs, the priming effect of type III latency cells must 
be due to viral protein(s) expressed during latency. We further iden-
tify EBV LMP-1 as the gene to prime cells for robust IFN production 
in EBV-infected B lymphocytes. 
The mechanisms of IFN production upon viral infection are under 
intensive investigation. However, the mechanism for IFN priming is 
not yet well understood. The stimulation of IFN production observed 
upon priming is known from an increase in the rate of IFN gene tran-
scription and requires an IFN-inducible factor(s) (17, 18). It seems 
likely that IRF-7 is an important factor in priming action of IFN be-
cause IRF-7 is inducible by IFN and IRF-7 is responsible for the ro-
bust and wide variety of type I IFN production (23, 55). It is of note 
that there is a striking similarity between IFN-primed and LMP-1-ex-
pressing cells: the high expression levels of ISGs including IRF-7. It 
is interesting that although LMP-1 is able to activate IRF-7, NF-κB, 
and ATF-2, three critical factors for type I IFN production, LMP-1 
apparently could not activate type I IFN production in viral latency 
but selectively induces ISGs (20, 24, 30). 
It is well known that NF-κB is an essential factor in type I IFN 
production (10, 11). The activation of NF-κB by LMP-1 is clearly 
involved in LMP-1-mediated priming action, at least in DG75 cells. 
LMP-DM failed to activate NF-κB and failed to prime cells. Block-
ing LMP-1-mediated NF-κB activation by IκB expression eliminated 
the priming function. NF-κB alone was able to induce the priming 
state. Thus, available data strongly suggest that NF-κB is necessary 
and sufficient for LMP-1-mediated priming effect in DG75 cells 
(Figure 5). 
The induction of ISGs, or IRF-7 in particular, may also be one of 
the molecular bases for the priming property of EBV latency cells. 
First, there is a great deal of correlative data to suggest that high IRF-
7 is associated with primed latency cells. IRF-7 is highly expressed 
in EBV type III latency cells, such as in BL41-EBV and Sav III (19, 
20). The high levels of IRF-7 in viral latency is primarily due to the 
expression of LMP-1 (20, 24). In DG75 cells, LMP-1 is able to in-
duce IRF-7 and is able to prime cells for IFN production; however, 
LMP-DM, which failed to induce the expression of IRF-7 (24), was 
unable to significantly induce IFN-β (Figure 4). Also, in the hu-
man 293 fibroblast cell line, LMP-1 failed to induce the expression 
of IRF-7 and failed to enhance IFN production upon viral infection 
(data not shown). Second, we have data to suggest that NF-κB is nec-
essary and sufficient to induce priming action in DG75 cells (Figure 
5). However, NF-κB alone is able to induce IRF-7 in DG75 cells, and 
LMP-1-mediated induction of IRF-7 also requires NF-κB (24). Thus, 
it is reasonable to suspect that IRF-7 is also involved in NF-κB-me-
diated priming processes. Third, ectopic expression of IRF-7 alone 
is sufficient to achieve the higher levels of IFN production (Figure 
Figure 5. NF-κB is involved in LMP-1-medi-
ated priming. A, NF-κB is essential for high 
IFN production. DG75 cells were transfected 
with pcDNA3, LMP-1, LMP-1 + IκB, or NF-κB 
(p65 + p50) expression plasmids. The trans-
fected cells were enriched and infected with 
Sendai virus for 6 h. IFN production was mea-
sured by RPA. The identity of RNAs is as 
shown. +/–, with or without virus infection. B, 
expression of target proteins in transfected 
cells. Lysates from transfected and enriched 
DG75 cells were used for Western blot anal-
ysis with LMP-1 and tubulin antibodies. The 
identity of proteins is as shown.
Figure 6.  IRF-7 may be involved for LMP-1-
medited priming. A, ectopic expression of IRF-
7 is sufficient to prime cells for IFN production. 
DG75 cells were transfected with IRF-7 or its mu-
tant IRF-7K92E expression plasmids. The trans-
fected cells were enriched and infected with Sen-
dai virus for 6 h. IFN production was measured by 
RPA. The identity of RNAs is as shown. +/–, with or 
without virus infection. B, expression of target pro-
teins in transfected cells. Lysates from transfected 
cells were used for Western blot analysis with IRF-
7 and tubulin antibodies. The identity of proteins is 
as shown.
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6). We also attempted to use small interfering RNA for IRF-7 (si-
IRF7) to block the production of IFN. Our siIRF-7 could only reduce 
LMP-1-mediated IRF-7 induction by about 50%, and we were un-
able to observe significant inhibition on IFN production under such 
reduction (data not shown). However, based on the well established 
role of IRF-7 in IFN production and the fact LMP-1 induces IRF-7, 
we suggest that IRF-7 may be one of the factors in the LMP-1-me-
diated priming process of EBV latency cells. Of note is that LMP-
1-mediated priming seems to be more efficient than that by overex-
pression of IRF-7 (Figure 6A), suggesting that an additional factor(s) 
may also be involved. To support this notion, BL41-EBV expressed 
higher levels of several cellular factors that are well known players 
in IFN production than BL41 cells based on microarray experiments 
(data not shown). It is obvious that more experiments are required to 
identify their roles in LMP-1-mediated priming. Finally, the induc-
tion of ISGs is apparently a common phenomenon in herpesviruses, 
and without the involvement of IFNs (56–60). Thus, based on our 
data presented here, it is likely that other herpesviruses might have a 
similar priming effect on IFN production. 
EBV has both latency and lytic replication in its life cycle. There 
is a constant battle between host and EBV in native environments. 
The success of EBV is likely dependent on its ability to keep laten-
cies under a variety of environments in vivo. By establishing laten-
cies, EBV can apparently escape host immune surveillance under 
various conditions. EBV latency can be disrupted into lytic replica-
tion by some chemical or physiological factors, including viral su-
perinfection (30). It is well known that IFNs inhibit viral replications, 
including herpesviruses (61–68). Thus, the inhibition of EBV lytic 
replication by IFNs is anticipated, and we did find that IFN-  was 
capable of inhibiting lytic replication of EBV (data not shown). EBV 
latency cells in vivo may also be under attacks from other viruses, 
the process of which may lead to lytic replications and disruption 
of EBV latency. Although we have used Sendai virus in this report, 
the robust induction of IFN by Sendai would suggest that other vi-
ruses may also behave similarly. IFN would be among the first genes 
to be synthesized and released upon viral superinfection. However, 
EBV lytic replication may take 24–48 h to complete. Therefore, high 
levels of IFNs from LMP-1-mediated priming would have opportu-
nities to preserve EBV latency in two fronts: 1) to prevent the vi-
ral superinfection and 2) to inhibit EBV lytic replication itself. How-
ever, if IFNs fail to preserve latency, EBV enters lytic replication and 
is able to use its lytic genes to block IFN functions. For example, 
EBV BZLF1 is able to block the functions of IRF-7 as well as STAT-
1 (69, 70). Finally, it is interesting to point out that EBV latency cells 
seem to be insensitive to the anti-proliferation effect of IFN, possibly 
due to the expression of EBNA-2 (71). Thus, IFN might inhibit EBV 
lytic replication without affecting the growth properties of EBV type 
III latency. 
In summary, our results indicate that LMP-1 primes viral latency 
cells for the production of type I IFNs upon viral superinfection and 
facilitates the antiviral effect of LMP-1. This report and our previ-
ous one (30) strongly suggest that LMP-1-mediated antiviral effect 
is likely to be an intrinsic property of EBV latency program, and this 
antiviral property may assist the establishment and/or maintenance of 
EBV latency. 
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